Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Myositis
What is your approach to treatment of severe intestinal vasculopathy in patients with myositis (such as NXP2)?
Answer from: at Academic Institution
Avoid NSAIDs and agents that can cause gastritis or GI ulcers. IVIG is the best treatment for such patients.
Sign In
or
Register
to read more
32700
Related Questions
What’s your drug of choice for patients with stable antisynthetase NSIP-ILD and overlap RA (CCP+) with significant polyarthritis as main manifestation?
How do you guide patients who seek online information about their disease to ensure it is accurate, supports their understanding, and minimizes unnecessary anxiety?
Do you consider immunosuppression in patients with a history of Sjogren's disease and clinical features of inclusion body myositis?
Is there a difference in efficacy between steroid-sparing agents like methotrexate, mycophenolate, and azathioprine in the treatment of immune-mediated myopathies?
How do you utilize tools such as MMT8 in clinical practice when evaluating myositis?
In patients with anti-PL7 antibody–associated antisynthetase syndrome, can sacroiliitis occur as part of the inflammatory arthritis spectrum, or should alternative causes be considered?
How do you approach incidental NXP-2 antibody positivity in patients without current clinical evidence of myositis or systemic autoimmune disease?
How do you approach management and monitoring of a patient with features suggestive of early or incomplete antisynthetase syndrome (mechanics hands and positive antisynthetase antibody) but no objective evidence of myositis, arthritis, or ILD at presentation?
Do you routinely perform muscle biopsies in patients presenting with the classic symptoms of Inclusion Body Myositis along with positive CN1A antibody?
How do you approach selecting optimal muscle biopsy site when evaluating a patient for suspected inflammatory myopathy?